<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539239</url>
  </required_header>
  <id_info>
    <org_study_id>CP-11-001</org_study_id>
    <nct_id>NCT01539239</nct_id>
  </id_info>
  <brief_title>Safety &amp; Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)</brief_title>
  <official_title>The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a prospective, randomized, controlled, multicenter, study. After
      informed consent is obtained, patients will be evaluated for eligibility based on glaucoma
      severity, eye health, and visual acuity. Following successful screening, use of all topical
      glaucoma medications will be stopped for a period of &quot;washout&quot; to establish a qualifying
      medication-free intraocular pressure (IOP) value. Clinical follow up will be scheduled over
      the course of the 24 month study, and examinations will be repeated to monitor eye health. At
      the 1 and 2 year follow up, those patients on ocular hypotensive medications will be
      instructed to washout, and then have the diurnal (IOP taken in the morning, mid-day, and
      afternoon in the same day) IOP evaluation. Annual follow up will occur up to 5 years. The
      primary effectiveness endpoint is a decrease in diurnal IOP from baseline compared to the 24
      months diurnal IOP following medication washout.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Mean Diurnal IOP From Baseline at 24 Months Following Medication Washout.</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Percentage of eyes in which diurnal IOP was reduced by greater than or equal to 20% at 24 months postoperative compared to baseline after washout of topical glaucoma medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Diurnal Washed Out IOP Change From Baseline at 24 Months Compared Between Treatment and Control Groups.</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Mean diurnal IOP change from baseline at 24 months between both groups after washout of topical glaucoma medications.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1143</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Hydrus Aqueous Implant (Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract surgery plus Hydrus Aqueous Implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cataract Surgery (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract surgery only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Aqueous Implant</intervention_name>
    <description>The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.</description>
    <arm_group_label>Hydrus Aqueous Implant (Treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>A monofocal intraocular lens (IOL) placed during the cataract surgery.</description>
    <arm_group_label>Cataract Surgery (Control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An operable age-related cataract

          -  A diagnosis of POAG treated with 1 to 4 hypotensive medications

          -  Medicated IOP ≤ 31 mmHg

          -  Diurnal IOP ≥ 22 mmHg and ≤ 34 mmHg

        Exclusion Criteria:

          -  Congenital or developmental glaucoma

          -  Previous argon laser trabeculoplasty

          -  Ab-interno or ab-externo device implanted in or through Schlemm's Canal

          -  Use of oral hypotensive medication for glaucoma for treatment of fellow eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Institute of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandwich</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boisbriand</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <results_first_submitted>August 14, 2019</results_first_submitted>
  <results_first_submitted_qc>September 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT01539239/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were screened and enrolled at 38 investigational sites in the United States and other countries.</recruitment_details>
      <pre_assignment_details>Of the 1,143 enrolled, 572 were screen failures and 15 were excluded intraoperatively due to failure to meet all intraoperative eligibility criteria. At the time of reporting, 556 patients randomized are available for analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydrus Aqueous Implant (Treatment)</title>
          <description>Cataract surgery plus Hydrus Aqueous Implant
Hydrus Aqueous Implant: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.</description>
        </group>
        <group group_id="P2">
          <title>Cataract Surgery (Control)</title>
          <description>Cataract surgery only
Cataract surgery: A monofocal intraocular lens (IOL) placed during the cataract surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="369"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) - All participants randomized and grouped according to their randomization assignment (as randomized). The ITT is used for the analyses of the primary and secondary effectiveness endpoints.</population>
      <group_list>
        <group group_id="B1">
          <title>Hydrus Aqueous Implant (Treatment)</title>
          <description>Cataract surgery plus Hydrus Aqueous Implant
Hydrus Aqueous Implant: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.</description>
        </group>
        <group group_id="B2">
          <title>Cataract Surgery (Control)</title>
          <description>Cataract surgery only
Cataract surgery: A monofocal intraocular lens (IOL) placed during the cataract surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="369"/>
            <count group_id="B2" value="187"/>
            <count group_id="B3" value="556"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="7.9"/>
                    <measurement group_id="B2" value="71.2" spread="7.6"/>
                    <measurement group_id="B3" value="71.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="513"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="444"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Mean Diurnal IOP From Baseline at 24 Months Following Medication Washout.</title>
        <description>Percentage of eyes in which diurnal IOP was reduced by greater than or equal to 20% at 24 months postoperative compared to baseline after washout of topical glaucoma medications.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Aqueous Implant (Treatment)</title>
            <description>Cataract surgery plus Hydrus Aqueous Implant
Hydrus Aqueous Implant: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.</description>
          </group>
          <group group_id="O2">
            <title>Cataract Surgery (Control)</title>
            <description>Cataract surgery only
Cataract surgery: A monofocal intraocular lens (IOL) placed during the cataract surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Mean Diurnal IOP From Baseline at 24 Months Following Medication Washout.</title>
          <description>Percentage of eyes in which diurnal IOP was reduced by greater than or equal to 20% at 24 months postoperative compared to baseline after washout of topical glaucoma medications.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2"/>
                    <measurement group_id="O2" value="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Diurnal Washed Out IOP Change From Baseline at 24 Months Compared Between Treatment and Control Groups.</title>
        <description>Mean diurnal IOP change from baseline at 24 months between both groups after washout of topical glaucoma medications.</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Aqueous Implant (Treatment)</title>
            <description>Cataract surgery plus Hydrus Aqueous Implant
Hydrus Aqueous Implant: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.</description>
          </group>
          <group group_id="O2">
            <title>Cataract Surgery (Control)</title>
            <description>Cataract surgery only
Cataract surgery: A monofocal intraocular lens (IOL) placed during the cataract surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Diurnal Washed Out IOP Change From Baseline at 24 Months Compared Between Treatment and Control Groups.</title>
          <description>Mean diurnal IOP change from baseline at 24 months between both groups after washout of topical glaucoma medications.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="4.1"/>
                    <measurement group_id="O2" value="-5.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>An adverse event is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device. All subjects who have been exposed to the study treatment were evaluated for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydrus Aqueous Implant (Treatment)</title>
          <description>Cataract surgery plus Hydrus Aqueous Implant
Hydrus Aqueous Implant: The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.</description>
        </group>
        <group group_id="E2">
          <title>Cataract Surgery (Control)</title>
          <description>Cataract surgery only
Cataract surgery: A monofocal intraocular lens (IOL) placed during the cataract surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BCVA loss greater than or equal to 2 lines ETDRS greater than or equal to 3 months</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Corneal Edema Mild to Mod after 1 month</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Glaucoma progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Neovascular Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Repair of malpositioned IOL haptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Orbital hemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the conjunctiva</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Worsening of visual field MD by greater than or equal to 2.5 dB compared with preoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Retinal Complications</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior uveitis/iritis (non-persistent)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="369"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Device obstruction, partial or complete</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Peripheral anterior synechiae without device obstruction</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Worsening of visual field MD by greater than or equal to 2.5 dB compared with preoperative</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sites participating in the trial may not publish their single center results until the aggregate study results have been published unless first obtaining written consent from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Hope</name_or_title>
      <organization>Ivantis</organization>
      <phone>949-333-1310</phone>
      <email>rhope@ivantisinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

